Skip to main content

Peter Wrighton-Smith

Inviata has appointed Peter Wrighton-Smith to its board of directors. He comes to Inviata's board with strategic product development and international commercialisation experience in addition to a broad understanding of the clinical service testing market. Wrighton-Smith is the current CEO and founder of Oxford Immunotec where he has overseen the company raise five rounds of venture funding prior to an IPO on NASDAQ in 2013.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.